New drug cocktail targets bulky head and neck tumors
NCT ID NCT07041788
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tests a new treatment for people with advanced head and neck cancer that has large tumors. The approach combines two immunotherapy drugs (iparomlimab and tuvonralimab) with special radiation and standard chemotherapy. The goal is to see if this combination can help patients live longer without their cancer growing or coming back. About 25 adults who have not had prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.